Skip to content

Advertisement

  • Poster presentation
  • Open Access

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy

  • 1,
  • 1 and
  • 2
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P53

https://doi.org/10.1186/2051-1426-3-S2-P53

Published: 4 November 2015

Keywords

  • Public Health
  • Immune Response
  • Cellular Immune Response
  • Gene Knockout
  • Mediate Approach

Background

Strategies that enhance the function of T cells are critical for immunotherapy.

Methods

Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1.

Results

We showed that the gene knockout of PD-1 by electroporation of plasmids encoding sgRNA and Cas9 was technically feasible. The disruption of PD-1 resulted in significant reduction of PD-1 expression but didn't affect the viability of primary human T cells. Cellular immune response of the gene modified T cells was characterized by up-regulated IFN-γ production and enhanced cytotoxicity.

Conclusions

These results suggest that we have established an approach for efficient checkpoint inhibitor disruption, providing a new strategy for targeting checkpoint inhibitors to improve the efficacy of T cell based adoptive therapies.

Declarations

Acknowledgements

The authors thank the entire Huang Lab and Liu Lab for their support and advice. This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81172281, 81000980, 81220108023, 81172094).

Authors’ Affiliations

(1)
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
(2)
The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China

References

  1. Topalian SL, Hodi S, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012, 366: 2443-2454.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, et al: Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014, 21 (3): 262-271.PubMedView ArticleGoogle Scholar
  3. Lloyd A, Vickery ON, Laugel B: Beyond the antigen receptor: editing the genome of T cells for cancer adoptive cellular therapies. Front Immunol. 2013, 4: 221-PubMedPubMed CentralView ArticleGoogle Scholar
  4. Li W, Teng F, Li T, Zhou Q: Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol. 2013, 31 (8): 684-686.PubMedView ArticleGoogle Scholar
  5. Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al: Generation of gene- modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013, 23: 720-723.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al: Generation of gene-modified Cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014, 156 (4): 1-8.View ArticleGoogle Scholar
  7. Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al: Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014, 11 (4): 399-402.PubMedView ArticleGoogle Scholar
  8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2014, 366 (26): 2443-2454.View ArticleGoogle Scholar
  9. Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, et al: siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T cell effector functions. Gene Therapy. 2012, 19 (10): 959-966.PubMedView ArticleGoogle Scholar
  10. Chicaybam L, Sodre AL, Curzio BA, Bonamino MH: An efficient low cost method for gene transfer to T lymphocytes. PLOS One. 2013, 8: e60298-PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© Su et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement